Minoryx Therapeutics

28 articles about Minoryx Therapeutics

• 

  Money on the Move: Sapience Scores $41m Backed by BMS, NexPoint

  6/2/2022

  Most money moves happened in Europe this week, including a government-backed award for Parkinson’s disease research and seed funding for an RNA platform.

• American Academy of Neurology (AAN 2022) – Braintale Showcases Together with Minoryx Data From Its Biomarker Platform for Disease and Treatment Monitoring of X-linked Adrenoleukodystrophy and Strengthens Collaboration

  4/25/2022

  Braintale, a medtech that is deciphering white matter, spin off from the Assistance Publique-Hôpitaux de Paris, showcases, with Minoryx, a biotechnology company developing a treatment for X-linked Adrenoleukodystrophy, the results of the multicentric ADVANCE sub study with Braintale biomarker platform on the occasion of the American Academy of Neurology.

• Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

  9/23/2020

  Minoryx will receive an upfront and milestone payments of up to $78 million, as well as double digit royalties on annual net sales

• 

  Clinical Catch-Up: May 11-15

  5/18/2020

  Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.

• Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD

  1/9/2020

  Minoryx Therapeutics, a company that specializes in the development of innovative treatments for orphan Central Nervous System (CNS) diseases, today announces that its lead drug candidate leriglitazone (MIN-102) has been granted fast track designation by the US Food and Drug Administration (FDA) for the treatment of all forms of X-linked adrenoleukodystrophy (X-ALD), including adrenomyeloneuropathy (AMN) and childhood cerebral ALD (cALD).  

• Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia

  11/12/2019

  Second Orphan Drug Designation granted by the European Commission for leriglitazone, in addition to X-linked adrenoleukodystrophy (X-ALD)

• Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia

  10/17/2019

  Minoryx Therapeutics announces that its lead drug candidate, leriglitazone (MIN-102), has been granted Orphan Drug Designation in Friedreich’s Ataxia by the US Food and Drug Administration (FDA).

• 

  Clinical Catch-Up: October 7-11

  10/14/2019

  It was a busy week for clinical trial announcements. Here’s a look.
• 

  BioSpace Global Roundup, Oct. 10

  10/10/2019

  Companies from across the globe provide updates on their business and pipelines.

• Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia

  10/8/2019

  Recruitment of 39 patients in multicenter European phase 2 trial completed ahead of schedule

• Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia

  6/4/2019

  Minoryx Therapeutics announces that the first patient has been dosed with its lead candidate, leriglitazone, in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia.

• Minoryx Therapeutics appoints Didier Le Normand as Group Chief Financial Officer (CFO) and General Manager of its Belgian subsidiary

  3/12/2019

  Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, announces that it has appointed Didier Le Normand as Group CFO as well as General Manager of its recently opened Belgian subsidiary.

• Minoryx Therapeutics receives approval from Spanish Regulatory Agency to initiate phase 2 study in Friedreich’s Ataxia

  2/27/2019

  Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has received approval from the Spanish Agency of Medicines and Medical Devices (AEMPS) to launch a phase 2 clinical trial in Friedreich’s Ataxia with its lead candidate, MIN-102.

• Minoryx Therapeutics extends its activities in Belgium

  1/15/2019

  Minoryx Therapeutics opens Belgian subsidiary that will lead important development activities

• Minoryx Therapeutics announces early completion of patient randomization in the ADVANCE trial: a phase 2/3 clinical study of MIN-102 in X-ALD patients

  12/12/2018

  Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has completed patient randomization of its phase 2/3 clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN). The trial enrolled adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD).

• Minoryx Therapeutics raises €21.3M in Series B funding round

  9/26/2018

  New investment will allow indication expansion of Minoryx’s lead compound, MIN-102

• Minoryx Therapeutics announces dosing of first US patient in phase 2/3 clinical study of MIN-102 (ADVANCE)

  9/10/2018

  ADVANCE trial recruitment is progressing rapidly in Europe with over 50 percent X-ALD patients enrolled

• Inthera Bioscience AG Expands Management Team with Seasoned Professionals and Secures €4.7 Million Second Tranche of €9.6 Million Series A Financing

  6/26/2018

  Inthera Bioscience AG today announced that three senior Pharma and Biotech Industry members joined its management team.

• Minoryx Therapeutics Announces the Dosing of First Patient in ADVANCE, a Phase II/III Clinical Study of MIN-102 in Patients With Adrenomyeloneuropathy (AMN)

  1/5/2018

  The trial enrolls adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy.

• Minoryx Therapeutics Successfully Completes Phase 1 Clinical Trial For Lead Candidate MIN-102

  3/21/2017